Candel Therapeutics (CADL) Stock Forecast and Price Target (2026)
Last updated November 2026
Short answer
9 analysts covering Candel Therapeutics (CADL) carry an average price target of $17.67 as of November 2026, +250.6% against the $5.04 share price on November 20, 2026. The published targets run from $11.00 to $29.00, a spread of 102% of the average, so the disagreement is wide. The rating split is 10 buy, 0 hold, 0 sell. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market. Walnut is not an investment adviser.
CADL analyst price targets
CADL analyst data as of November 2026, sourced from Yahoo Finance and may be delayed. The price is the last one Yahoo Finance reported on November 20, 2026.A price target is what an analyst published on a date, not a forecast Walnut endorses, and targets are typically set on a 12-month view. Verify current figures before deciding.
The average target of $17.67 sits well above the $5.04 price, +250.6%. The median is $18.00, and where the two differ the median is the steadier read, because one unusually high or low target cannot drag it.
What the CADL target range actually tells you
The published targets span $11.00 to $29.00. That gap is 102% of the average target, which counts as wide disagreement. A spread that wide is the most informative number on this page: analysts who all follow the company closely cannot agree within a factor that large, which means the outcome depends on assumptions nobody can settle yet.
The useful move is to read the high target as one bull scenario and the low target as one bear scenario, then ask which set of assumptions you find more plausible. Both cases are worked through on the CADL is it a buy page.
Recent analyst actions on CADL
| Firm | Action | Target | Prior | Date |
|---|---|---|---|---|
| Citigroup | Lowered (Buy) | $20.00 | $26.00 | November 16, 2026 |
| HC Wainwright & Co. | Lowered (Buy) | $18.00 | $23.00 | November 13, 2026 |
| Canaccord Genuity | Lowered (Buy) | $13.00 | $25.00 | November 13, 2026 |
| Stifel | Lowered (Buy) | $19.00 | $22.00 | November 13, 2026 |
| Jefferies | Initiated (Buy) | $25.00 | - | October 22, 2026 |
| B of A Securities | Raised (Buy) | $18.00 | $12.00 | September 21, 2026 |
| B of A Securities | Raised (Neutral) | $12.00 | $9.00 | August 14, 2026 |
| HC Wainwright & Co. | Maintained (Buy) | $23.00 | $23.00 | August 13, 2026 |
| Stifel | Initiated (Buy) | $22.00 | - | July 13, 2026 |
The most recent published rating actions on CADL within the last six months, from Yahoo Finance. Each row is dated because a target only means something alongside the date it was set. Walnut is not an investment adviser and does not endorse any of these views.
In the last six months there have been 2 raises and 4 cuts among these actions. The direction of revisions is often more telling than the level, because it shows which way informed opinion is moving.
How analysts rate CADL
Of the analysts with a published rating, 10 say buy, 0 say hold, and 0 say sell, so 100% carry a buy. That buy share has risen over the last three months, so sentiment is drifting more positive.
The distribution says more than the label. Sell ratings are rare across the entire market for structural reasons, so a stock with no sell ratings is unremarkable, while even a handful of them is worth understanding.
Why a CADL price target is not a prediction
- It is a 12-month model output. An analyst picks assumptions for revenue, margin, and a multiple, and the target falls out of the arithmetic. Change one assumption and the target moves a lot.
- The distribution is skewed. Sell-side coverage carries far more buy ratings than sell ratings across the whole market, so the average is not a balanced vote.
- Targets follow price as often as they lead it. Revisions frequently arrive after a move, not before, which is why a rising target is weak evidence on its own.
- Nobody is scored on it. There is no cost to a target that never gets close, so treat accuracy as unverified unless you check the firm's record yourself.
CADL earnings and revenue forecast
For the fiscal year ending Dec 2026, the 2 analysts publishing estimates on CADL expect earnings of -$1.18 per share.
| Period | EPS estimate | EPS growth | Revenue estimate | Revenue growth |
|---|---|---|---|---|
Quarter ending Dec 2026 next quarter to report, 2 analysts | -$0.30 -$0.31 to -$0.30 | n/a | - | - |
Quarter ending Mar 2027 the quarter after, 1 analyst | -$0.34 | n/a | - | - |
Fiscal year ending Dec 2026 fiscal year next to report, 2 analysts | -$1.18 -$1.23 to -$1.13 | n/a | - | - |
Fiscal year ending Dec 2027 the fiscal year after, 9 analysts | -$1.44 -$1.52 to -$1.35 | n/a | $9.9 million $0 thousand to $66.6 million | +0.0% |
Consensus estimates for CADL published by sell-side analysts, as of November 2026, from Yahoo Finance. Each figure is the average of the analysts counted, with the lowest and highest estimate beneath it; growth compares with the same period a year earlier and is left blank where either figure is a loss. Estimates change constantly. Walnut is not an investment adviser.
Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level. Candel Therapeutics next reports around November 13, 2026 (an estimated date), which is when these figures get tested against actual results.
Is there a 2030 forecast for CADL?
Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering CADL do not put out a 2030 number. Anything presenting one is extrapolating a growth rate of its own, and a figure produced that way tells you about the assumption chosen, not about the company.
What can be said over a long horizon is what the current price already assumes about the business, which is a question the filings answer and a forecast cannot.
For a ten-year question, that frame is more useful. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Candel Therapeutics can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.
What could move CADL from here
In short: the drivers cited most often are The prostate cancer filing in mid-2027, Manufacturing readiness, AURORA, the Phase 3 lung cancer trial. The risk cited most often against it is the main risk is regulatory.
Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the CADL is it a buy page.
Your questions about Candel Therapeutics
Ask Walnut's AI anything about CADL and see how it fits what you own.
FAQ
What is the price target for Candel Therapeutics (CADL)?
+
The average analyst price target for CADL is $17.67 as of November 2026, across 9 analysts. The average is +250.6% against the $5.04 share price on November 20, 2026, so the consensus sits well above where the stock trades. The median target, which is less distorted by one extreme view, is $18.00. Targets move constantly; verify the current figure before relying on it.
How high could CADL go?
+
The highest published target is $29.00, which is +475.4% against the $5.04 price. It is one analyst's most optimistic case, not a ceiling and not a forecast. The lowest is $11.00. The gap between them answers this question best: analysts who all follow Candel Therapeutics closely disagree by 102% of the average target, so treat any single number as one scenario.
How many analysts cover CADL?
+
9 analysts publish estimates on CADL as of November 2026. Of those with a published rating, 10 say buy, 0 hold, and 0 sell, so 100% carry a buy rating. More coverage usually means the consensus is better informed, though it also means the obvious points are already in the price.
Are analyst price targets for CADL accurate?
+
Treat them as informed opinion, not measurement. Two things matter here. Sell-side ratings skew positive across the market, and CADL is no exception at 100% buy ratings, so the distribution is not a balanced vote. And targets tend to follow the share price at least as often as they lead it, getting raised after a stock has already run. They are most useful as a read on what the informed consensus expects, and least useful as a prediction of where the price lands.
Has the CADL price target been raised or cut recently?
+
In the last six months there have been 2 raises and 4 cuts among the published actions on CADL. The most recent was Citigroup, which lowered its target to $20.00 from $26.00 on November 16, 2026. The direction of revisions often tells you more than the level, because it shows which way the informed view is moving.
Is analyst sentiment on CADL improving?
+
Over the last three months the share of analysts rating CADL a buy has been rising. The shift is in opinion, not in the business, and it often lags the news that caused it. It is best read alongside the target revisions.
What are analysts' earnings estimates for Candel Therapeutics (CADL)?
+
For the fiscal year ending Dec 2026, the 2 analysts publishing estimates on CADL expect earnings of -$1.18 per share. For the fiscal year ending Dec 2027, the consensus is -$1.44 per share. These are consensus estimates as of November 2026, the average of what the covering analysts publish, and they are revised constantly, especially around each earnings report. They describe expectations, not results.
When does CADL report earnings next?
+
Candel Therapeutics's next earnings report is expected around November 13, 2026, a date estimated from its reporting history that the company has not yet confirmed. The report is when the estimates on this page get tested against actual results, which is why targets and estimates tend to move most in the days after it.
What is the CADL stock price prediction for 2030?
+
There is no published one. Analyst targets run to about twelve months and no firm covering CADL publishes a 2030 figure, so any site showing one has extrapolated a growth rate of its own. The answerable version of the question is what the current price already assumes about Candel Therapeutics's earnings, which the forward multiple on this page sets out, and what would have to change for that to break.
Will CADL go up in 2026?
+
Nobody knows, including the analysts publishing targets. What the numbers on this page tell you is where informed opinion currently sits and how much it disagrees with itself, which is useful and different from a prediction. The risk most often cited against Candel Therapeutics: The main risk is regulatory. Walnut is not an investment adviser.
Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a November 2026 data pull of published third-party research, are approximate, and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026, and every percentage against it on this page is measured from that price. Verify current figures with your broker before acting on them.